Press Releases OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-31 EDT			5-day change	1st Jan Change
1.49 ^USD	+7.19%		+12.88%	-15.82%

03-22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
03-22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OKYO Pharma Announces Participation in May 2024 Investor Conferences	05-08	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)	04-30	AQ
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024	04-08	AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery	04-02	AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	03-22	AQ
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event	03-20	AQ
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	02-09	AQ
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board	01-31	AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease	01-08	AQ
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024	01-05	AQ
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K	12-18	PU
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	12-04	AQ
Notice of AGM: December 2023	11-28	PU
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction	23-10-31	AQ
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)	23-10-09	AQ
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")	23-10-05	AQ
OKYO Pharma's Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)	23-10-05	AQ
OKYO PHARSADR : Securities Purchase Agreement - Form 6-K	23-09-15	PU
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares	23-09-15	AQ
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares	23-09-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Press Releases

Filters